Vivity Insight: A Study of Patient Satisfaction and Visual Performance

Overview

This will be a single arm, open-label, prospective study of patient-reported outcomes of patients with bilateral implantation of the Vivity or Vivity Toric implant.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 1, 2021

Detailed Description

Existing diffractive extended depth of focus (EDOF) lenses provide two adjacent "zones" of uncorrected vision (distance and intermediate or intermediate and near) but have a track record of frequent patient dissatisfaction because of unwanted visual side effects, "spider webs" or haloes. The Vivity non-diffractive EDOF lens offers this same range ofvision with contrast sensitivity similar to a monofocal lens, which suggests fewer side effects will be encountered in clinical practice.

This study is designed to measure postoperative patient-reported outcomes with this new lens implant. Previous studies we have conducted on the bilateral ReSTOR 3.0, ReSTOR with ActiveFocus 2.5 (mixed with 3.0 and alone with mini-monovision) have shown high satisfaction, spectacle independence, and acceptable glare and halo profiles using a validated questionnaire instrument developed by MDbackline, Inc. The postoperative portions of this study will be designed to mirror those previous studies using the same instrument.

All subjects will receive the Vivity or Vivity Toric implant binocularly with a target of plano sphere.

Interventions

  • Device: Alcon Vivity or Vivity Toric IOL
    • Patients who previously underwent cataract surgery with the Alcon Vivity or Vivity Toric IOL in both eyes.

Clinical Trial Outcome Measures

Primary Measures

  • Percentage of patients reporting “not at all” or “just a little” when asked, “With or without glasses, how much do you notice glare or haloes around lights in dim light situations?”
    • Time Frame: 8/1/2020 – 7/1/2021
    • Percentage of patients reporting “not at all” or “just a little” when asked, “With or without glasses, how much do you notice glare or haloes around lights in dim light situations?”

Secondary Measures

  • Percentage of postoperative patients who report “rarely” when asked “How often do you need glasses to see the computer?”
    • Time Frame: 8/1/2020 – 7/1/2021
    • Percentage of postoperative patients who report “rarely” when asked “How often do you need glasses to see the computer?”
  • Percentage of postoperative patients who report that they do not require reading glasses for various activities
    • Time Frame: 8/1/2020 – 7/1/2021
    • Percentage of postoperative patients who report that they do not require reading glasses for various activities (driving, reading, including fine print, seeing computer monitor, watching TV, sports/hobbies when asked “For what types of activities do you need glasses to see (other than sunglasses)?”

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with cataract and otherwise healthy eyes, not exhibiting any significant ocular morbidity that would be expected to influence outcome measures.
  • Patients implanted with Vivity or Vivity Toric lenses bilaterally within 6 months of the survey administration.
  • Patients whose postoperative manifest refraction at the time of the survey is within ± 0.5 D sphere and ≤0.75 D of cylindrical refraction.
  • Patients who have given consent to participate in the survey.

Exclusion Criteria

  • Patients with visually significant co-morbidities (corneal, retina, optic nerve disease) that could affect their satisfaction with surgery.
  • Patients with surgical complications either during or after surgery (capsule tears, iris trauma, decentered IOL, cystoid macular edema, etc.) that would, the judgement of the investigator, influence the outcome measures of the study.
  • Patients with previous refractive surgery within the past 6 months prior to cataract surgery.
  • Patients with > grade 1 posterior capsule opacity at their last visit.
  • Patients who do not meet the refractive endpoints described in the Inclusion Criteria.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Research Insight LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • John Hovanesian, MD, 949-742-3937, jhovanesian@researchinsightca.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.